Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer.

Male Humans Aged Female Positron Emission Tomography Computed Tomography Prostatic Neoplasms, Castration-Resistant / diagnostic imaging Reproducibility of Results Retrospective Studies Physicians

Journal

Radiology
ISSN: 1527-1315
Titre abrégé: Radiology
Pays: United States
ID NLM: 0401260

Informations de publication

Date de publication:
07 2023
Historique:
pmc-release: 01 07 2024
medline: 13 7 2023
pubmed: 11 7 2023
entrez: 11 7 2023
Statut: ppublish

Résumé

Background Response Evaluation Criteria in Prostate-specific Membrane Antigen (PSMA) PET/CT (RECIP 1.0) initially integrated software-based quantitative assessment of PSMA-positive total tumor volume (TTV). Clinical implementation of such software is not expected soon, limiting the use of RECIP in practice. Purpose To assess the agreement of RECIP determined using tumor segmentation software (quantitative RECIP) with RECIP determined by qualitative reads by nuclear medicine physicians (visual RECIP) for response evaluation in metastatic castration-resistant prostate cancer. Materials and Methods This multicenter retrospective study at three academic centers included men who received lutetium 177 (

Identifiants

DOI: 10.1148/radiol.222148 PMID: 37432081 PMC: PMC10374938
pubmed: 37432081
doi: 10.1148/radiol.222148
pmc: PMC10374938
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e222148

Références

Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
Biochem Med (Zagreb). 2012;22(3):276-82
pubmed: 23092060
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
J Nucl Med. 2018 Mar;59(3):469-478
pubmed: 29123012
J Nucl Med. 2022 Feb;63(2):233-239
pubmed: 34049980
Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4271-4281
pubmed: 35767071
J Nucl Med. 2022 Nov;63(11):1651-1658
pubmed: 35422442
Lancet Oncol. 2021 Aug;22(8):1115-1125
pubmed: 34246328
J Nucl Med. 2019 Sep;60(9):1277-1283
pubmed: 30850484
Tomography. 2018 Dec;4(4):182-193
pubmed: 30588504

Auteurs

Andrei Gafita (A)

From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology (A.G., L.D., J.C., M.R.B., A.F.), Department of Medicine and Urology, David Geffen School of Medicine (M.R.), and Department of Radiological Sciences (M.R.B.), University of California-Los Angeles, Los Angeles, Calif; Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St, JHOC 3225A, Baltimore, MD 21287 (A.G., S.P.R.); Department of Nuclear Medicine, Université Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France (L.D.); Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany (I.R., M.E.); Departments of Nuclear Medicine (W.P.F., K.H., M.R.B.) and Urology (B.H.), University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany; Department of Medicine, VA Greater Los Angeles, Los Angeles, Calif (M.R.); and Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (A.F.).
ORCID: 0000-0002-4865-9192

Loïc Djaileb (L)

From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology (A.G., L.D., J.C., M.R.B., A.F.), Department of Medicine and Urology, David Geffen School of Medicine (M.R.), and Department of Radiological Sciences (M.R.B.), University of California-Los Angeles, Los Angeles, Calif; Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St, JHOC 3225A, Baltimore, MD 21287 (A.G., S.P.R.); Department of Nuclear Medicine, Université Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France (L.D.); Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany (I.R., M.E.); Departments of Nuclear Medicine (W.P.F., K.H., M.R.B.) and Urology (B.H.), University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany; Department of Medicine, VA Greater Los Angeles, Los Angeles, Calif (M.R.); and Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (A.F.).
ORCID: 0000-0003-2784-6367

Isabel Rauscher (I)

From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology (A.G., L.D., J.C., M.R.B., A.F.), Department of Medicine and Urology, David Geffen School of Medicine (M.R.), and Department of Radiological Sciences (M.R.B.), University of California-Los Angeles, Los Angeles, Calif; Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St, JHOC 3225A, Baltimore, MD 21287 (A.G., S.P.R.); Department of Nuclear Medicine, Université Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France (L.D.); Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany (I.R., M.E.); Departments of Nuclear Medicine (W.P.F., K.H., M.R.B.) and Urology (B.H.), University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany; Department of Medicine, VA Greater Los Angeles, Los Angeles, Calif (M.R.); and Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (A.F.).
ORCID: 0000-0003-4655-2153

Wolfgang P Fendler (WP)

From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology (A.G., L.D., J.C., M.R.B., A.F.), Department of Medicine and Urology, David Geffen School of Medicine (M.R.), and Department of Radiological Sciences (M.R.B.), University of California-Los Angeles, Los Angeles, Calif; Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St, JHOC 3225A, Baltimore, MD 21287 (A.G., S.P.R.); Department of Nuclear Medicine, Université Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France (L.D.); Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany (I.R., M.E.); Departments of Nuclear Medicine (W.P.F., K.H., M.R.B.) and Urology (B.H.), University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany; Department of Medicine, VA Greater Los Angeles, Los Angeles, Calif (M.R.); and Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (A.F.).

Boris Hadaschik (B)

From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology (A.G., L.D., J.C., M.R.B., A.F.), Department of Medicine and Urology, David Geffen School of Medicine (M.R.), and Department of Radiological Sciences (M.R.B.), University of California-Los Angeles, Los Angeles, Calif; Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St, JHOC 3225A, Baltimore, MD 21287 (A.G., S.P.R.); Department of Nuclear Medicine, Université Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France (L.D.); Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany (I.R., M.E.); Departments of Nuclear Medicine (W.P.F., K.H., M.R.B.) and Urology (B.H.), University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany; Department of Medicine, VA Greater Los Angeles, Los Angeles, Calif (M.R.); and Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (A.F.).
ORCID: 0000-0002-1052-2692

Steven P Rowe (SP)

From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology (A.G., L.D., J.C., M.R.B., A.F.), Department of Medicine and Urology, David Geffen School of Medicine (M.R.), and Department of Radiological Sciences (M.R.B.), University of California-Los Angeles, Los Angeles, Calif; Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St, JHOC 3225A, Baltimore, MD 21287 (A.G., S.P.R.); Department of Nuclear Medicine, Université Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France (L.D.); Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany (I.R., M.E.); Departments of Nuclear Medicine (W.P.F., K.H., M.R.B.) and Urology (B.H.), University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany; Department of Medicine, VA Greater Los Angeles, Los Angeles, Calif (M.R.); and Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (A.F.).
ORCID: 0000-0003-2897-4694

Ken Herrmann (K)

From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology (A.G., L.D., J.C., M.R.B., A.F.), Department of Medicine and Urology, David Geffen School of Medicine (M.R.), and Department of Radiological Sciences (M.R.B.), University of California-Los Angeles, Los Angeles, Calif; Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St, JHOC 3225A, Baltimore, MD 21287 (A.G., S.P.R.); Department of Nuclear Medicine, Université Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France (L.D.); Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany (I.R., M.E.); Departments of Nuclear Medicine (W.P.F., K.H., M.R.B.) and Urology (B.H.), University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany; Department of Medicine, VA Greater Los Angeles, Los Angeles, Calif (M.R.); and Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (A.F.).
ORCID: 0000-0002-9662-7259

Jeremie Calais (J)

From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology (A.G., L.D., J.C., M.R.B., A.F.), Department of Medicine and Urology, David Geffen School of Medicine (M.R.), and Department of Radiological Sciences (M.R.B.), University of California-Los Angeles, Los Angeles, Calif; Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St, JHOC 3225A, Baltimore, MD 21287 (A.G., S.P.R.); Department of Nuclear Medicine, Université Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France (L.D.); Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany (I.R., M.E.); Departments of Nuclear Medicine (W.P.F., K.H., M.R.B.) and Urology (B.H.), University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany; Department of Medicine, VA Greater Los Angeles, Los Angeles, Calif (M.R.); and Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (A.F.).
ORCID: 0000-0002-8839-4379

Matthew Rettig (M)

From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology (A.G., L.D., J.C., M.R.B., A.F.), Department of Medicine and Urology, David Geffen School of Medicine (M.R.), and Department of Radiological Sciences (M.R.B.), University of California-Los Angeles, Los Angeles, Calif; Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St, JHOC 3225A, Baltimore, MD 21287 (A.G., S.P.R.); Department of Nuclear Medicine, Université Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France (L.D.); Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany (I.R., M.E.); Departments of Nuclear Medicine (W.P.F., K.H., M.R.B.) and Urology (B.H.), University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany; Department of Medicine, VA Greater Los Angeles, Los Angeles, Calif (M.R.); and Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (A.F.).
ORCID: 0000-0002-7394-3056

Matthias Eiber (M)

From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology (A.G., L.D., J.C., M.R.B., A.F.), Department of Medicine and Urology, David Geffen School of Medicine (M.R.), and Department of Radiological Sciences (M.R.B.), University of California-Los Angeles, Los Angeles, Calif; Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St, JHOC 3225A, Baltimore, MD 21287 (A.G., S.P.R.); Department of Nuclear Medicine, Université Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France (L.D.); Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany (I.R., M.E.); Departments of Nuclear Medicine (W.P.F., K.H., M.R.B.) and Urology (B.H.), University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany; Department of Medicine, VA Greater Los Angeles, Los Angeles, Calif (M.R.); and Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (A.F.).
ORCID: 0000-0003-2130-644X

Manuel Weber (M)

From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology (A.G., L.D., J.C., M.R.B., A.F.), Department of Medicine and Urology, David Geffen School of Medicine (M.R.), and Department of Radiological Sciences (M.R.B.), University of California-Los Angeles, Los Angeles, Calif; Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St, JHOC 3225A, Baltimore, MD 21287 (A.G., S.P.R.); Department of Nuclear Medicine, Université Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France (L.D.); Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany (I.R., M.E.); Departments of Nuclear Medicine (W.P.F., K.H., M.R.B.) and Urology (B.H.), University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany; Department of Medicine, VA Greater Los Angeles, Los Angeles, Calif (M.R.); and Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (A.F.).
ORCID: 0000-0002-9000-1319

Matthias R Benz (MR)

From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology (A.G., L.D., J.C., M.R.B., A.F.), Department of Medicine and Urology, David Geffen School of Medicine (M.R.), and Department of Radiological Sciences (M.R.B.), University of California-Los Angeles, Los Angeles, Calif; Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St, JHOC 3225A, Baltimore, MD 21287 (A.G., S.P.R.); Department of Nuclear Medicine, Université Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France (L.D.); Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany (I.R., M.E.); Departments of Nuclear Medicine (W.P.F., K.H., M.R.B.) and Urology (B.H.), University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany; Department of Medicine, VA Greater Los Angeles, Los Angeles, Calif (M.R.); and Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (A.F.).

Andrea Farolfi (A)

From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology (A.G., L.D., J.C., M.R.B., A.F.), Department of Medicine and Urology, David Geffen School of Medicine (M.R.), and Department of Radiological Sciences (M.R.B.), University of California-Los Angeles, Los Angeles, Calif; Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St, JHOC 3225A, Baltimore, MD 21287 (A.G., S.P.R.); Department of Nuclear Medicine, Université Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France (L.D.); Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany (I.R., M.E.); Departments of Nuclear Medicine (W.P.F., K.H., M.R.B.) and Urology (B.H.), University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany; Department of Medicine, VA Greater Los Angeles, Los Angeles, Calif (M.R.); and Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (A.F.).
ORCID: 0000-0002-5443-4301

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Response Evaluation Criteria in PSMA PET/CT...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Response Evaluation Criteria in PSMA PET/CT...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › Response Evaluation Criteria in PSMA PET/CT...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Tumeurs prostatiques résistantes à la castration › Response Evaluation Criteria in PSMA PET/CT...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Reproductibilité des résultats › Response Evaluation Criteria in PSMA PET/CT...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Response Evaluation Criteria in PSMA PET/CT...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Personnel de santé › Médecins › Response Evaluation Criteria in PSMA PET/CT...